Business Context and Reporting Period
Company: Penumbra, Inc. (PEN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: Penumbra is the world's leading thrombectomy company, developing technologies for ischemic stroke, venous thromboembolism, and acute limb ischemia. The company operates as a single segment focused on the design, development, manufacturing, and marketing of innovative medical products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $374.8 million | $324.1 million |
| Gross Profit | $253.4 million | $215.9 million |
| Gross Margin | 67.6% | 66.6% |
| Operating Income | $38.2 million | $40.4 million |
| Net Income | $32.6 million | $39.2 million |
| Diluted EPS | $0.82 | $1.00 |
| Operating Cash Flow | $87.0 million | $49.0 million |
| Cash & Cash Equivalents | $241.3 million | $376.1 million |
| Marketable Investments | $374.4 million | $357.9 million |
| Total Assets | $1,898.4 million | $1,826.5 million |
| Working Capital | $1,063.7 million | $1,033.6 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 15.6% year-over-year, driven by higher sales volume in both thrombectomy (+12.1%) and embolization/access (+23.8%) product lines. Growth was primarily attributed to market penetration in the United States.
- Operating Expenses: Total operating expenses rose 22.6% to $215.2 million. Sales, General, and Administrative (SG&A) expenses increased significantly by 25.6% ($39.3 million), driven by a $17.2 million increase in personnel costs and a $9.4 million increase in acquisition-related professional fees associated with the pending merger.
- Profitability: Despite revenue growth, Net Income decreased 16.9% to $32.6 million. This decline was primarily due to the surge in SG&A expenses and a higher effective tax rate (21.8% vs. 10.6% in the prior year), which resulted from a decrease in excess tax benefits from stock-based compensation.
- Cash Flow: Net cash provided by operating activities improved significantly to $87.0 million, up from $49.0 million, aided by favorable changes in working capital, specifically a $16.9 million increase in accrued expenses and a $5.5 million decrease in accounts receivable.
Guidance, Outlook, and Material Events
Pending Merger with Boston Scientific
On January 14, 2026, Penumbra entered into a definitive agreement to be acquired by Boston Scientific Corporation. Key terms include:
- Valuation: Enterprise value of approximately $14.5 billion.
- Consideration: $374 per share, paid approximately 73% in cash and 27% in Boston Scientific common stock.
- Timeline: Expected to close in 2026, subject to shareholder and regulatory approvals.
- Termination Fees: Penumbra would pay $525 million if it terminates under certain circumstances; Boston Scientific would pay $900 million if it terminates under certain circumstances.
Capital Expenditures and Expansion
The company is constructing a new manufacturing facility and warehouse in Costa Rica. The total project cost is estimated at $88 million (increased by $28 million in Q1 2026 due to scope refinements). As of March 31, 2026, $42.4 million has been paid.
Risks and Contingencies
- Legal Proceedings: A class action lawsuit regarding wages and overtime was settled for $4.6 million in March 2025, with final court approval granted in February 2026. Payments were substantially completed.
- Tariffs: The company is monitoring the impact of a U.S. Supreme Court ruling invalidating certain tariffs imposed under the International Emergency Economic Powers Act (IEEPA) and subsequent orders for refunds.
- Foreign Exchange: Approximately 20.9% of revenue is international, primarily denominated in euros. The company does not currently hedge foreign exchange exposure.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of shareholder approvals and regulatory clearances required to close the Boston Scientific acquisition.
- SG&A Expense Sustainability: Assess whether the $9.4 million in acquisition-related professional fees and the $17.2 million personnel increase are one-time costs or indicative of a new baseline for operating expenses.
- Costa Rica Facility Progress: Monitor the timeline and budget adherence for the $88 million Costa Rica manufacturing expansion.
- Tax Rate Volatility: Review future effective tax rates, noting the significant variance caused by stock-based compensation tax benefits in the current period.
- Inventory Levels: Inventory increased by $7.0 million to $438.5 million; verify that this buildup aligns with demand forecasts and does not signal future write-downs.